88 citations · 126 across the 9 of their papers we have counts for
9 papers
A Bayesian design for dual-agent dose optimization with targeted therapies
José L. Jiménez, Mourad Tighiouart
In this article, we propose a phase I-II design in two stages for the combination of molecularly targeted therapies. The design is motivated by a published case study that combines…
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Mourad Tighiouart, José L. Jiménez, Marcio A. Diniz +1
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there…
Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials
José L. Jiménez, Mourad Tighiouart
Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where efficacy cannot be ascertained in a short period of time, it is common to divid…
Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
Márcio A. Diniz, Gillian Gresham, Sungjin Kim +6
We propose to apply stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials. We defined five levels of refinement for…
A Nonparametric Bayesian Design for Drug Combination Cancer Trials
Zahra S. Razaee, Galen Wien-Cook, Mourad Tighiouart
We propose an adaptive design for early phase drug combination cancer trials with the goal of estimating the maximum tolerated dose (MTD). A nonparametric Bayesian model, using bet…
A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations
José L. Jiménez, Sungjin Kim, Mourad Tighiouart
The use of drug combinations in clinical trials is increasingly common during the last years since a more favorable therapeutic response may be obtained by combining drugs. In phas…
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
Jose L. Jimenez, Mourad Tighiouart, Mauro Gasparini
Drug combination trials are increasingly common nowadays in clinical research. However, very few methods have been developed to consider toxicity attributions in the dose escalatio…
Comparison between continuous and discrete doses using Escalation With Overdose Control
Márcio Augusto Diniz, Mourad Tighiouart, André Rogatko
Although there is an extensive statistical literature showing the disadvantages of discretizing continuous variables, categorization is a common practice in clinical research which…
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
Mourad Tighiouart, André Rogatko
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment effica…